Our findings indicate that CD4+TILs correlate with a favorable prognosis in NSCLC patients with no statistical significance, whereas CD8+TILs are associated with enhanced OS(with statistically significant), aligning with prior research outcomes (82). The gene discussed is CD4; the disease is non-small cell lung carcinoma.